Viewing Study NCT01168050

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:24 PM
Ignite Modification Date: 2026-01-22 @ 2:59 PM
Study NCT ID: NCT01168050
Status: UNKNOWN
Last Update Posted: 2011-02-08
First Post: 2010-07-21
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
Sponsor: Assistance Publique - Hôpitaux de Paris
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Malignant Skin Melanoma T0 View
None Stage III Melanoma View
None Stage IV Melanoma View
None Amplification View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Malignant Skin Melanoma T0 View
None stage III unresectable melanomas, View
None or stage IV melanomas with c-KIT mutation View
None or amplification. View